Skip to content
Storytelling Co – Lifestyle
Author:
Sensorium Therapeutics, Inc
Sensorium Therapeutics Announces Positive Phase 1a Data for SNTX-2643 Showing Rapid and Sustained CNS Pharmacodynamic Activity
September 21, 2026